Catalyst
Slingshot members are tracking this event:
BioMarin (BMRN) Expects Decision from CHMP and EU on CLN2 Disease Treatment Brineura in Q3 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMRN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2017
Occurred Source:
http://investors.biomarin.com/2017-06-01-European-Commission-Approves-Brineura-TM-cerliponase-alfa-the-First-Treatment-for-CLN2-Disease-a-Form-of-Batten-Disease-and-Ultra-Rare-Brain-Disorder-in-Children
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Chmp, European Commission, Brineura
